Expression of E-cadherin and β-catenin in gastric carcinoma and its correlation with the clinicopathological features and patient survival

Table 1 Abnormal expression of E-cadherinin and β-catenin in gastric carcinoma and precancerous condition

	Total n	E-cadherin n(%)	β-catenin n(%)
Gastric carcinoma	163	75 (46.0)	73 (44.8)
Dysplasia	44	16 (36.4)	7 (15.9)
Intestinal metaplasia	25	0	0
Atrophic gastritis	28	0	0
Health controls	12	0	0

Table 2 Expression of E-cadherin or β-catenin and Gross Ap-pearance

	No	E-cadherin expression (%)		β-catenin expression (%)
		Abnormal	P value	Abnormal	P value
Tumor size (cm)	163
0-4.9	48	16 (33.3)		14 (28.2)
5.0-9.9	76	30 (35.5)	16.58	29 (36.2)	21.41
≥ 10.0	39	29 (74.4)	< 0.005a	30 (78.9)	< 0.005a
Gross appearance	139
BorrmannI	12	1 (8.3)		2 (16.7)
BorrmannII	16	3 (18.8)		3 (18.8)
BorrmannIII	80	35 (43.8)	11.92	32 (40.0)	9.65
BorrmannIV	31	21 (67.7)	< 0.005b	24 (77.4)	< 0.005b

^a≥ 10.0 group vs 0-4.9 or 5-9.9 group;

^bBorrmann IIIand Borrmann IVgroups vs BorrmannI and Borrmann IIgroups

Table 3 Relationship Between Expression of E-cadherin or β-catenin and Histopathological Features in Gastric Carcinoma

	No	E-cadherin expression (%)		β-catenin expression (%)
		Abnormal	P value	Abnormal	P value
pT category
T1/T2	65	28 (43.1)		29 (44.6)
T3/T4	98	47 (48.0)	NS	44 (44.9)	NS
pN category
N-negative	71	29 (40.8)		20 (28.2)	14.56
N-positive	92	46 (50.0)	NS	53 (57.6)	< 0.005
WHO classification
Adenocarcinoma	160
Papillary	16	3 (18.8)a		2 (7.1)a
Tubular	109	48 (44.0)		46 (42.2)
Mucinous	24	13 (54.2)	8.47	15 (62.5)	7.05
Signet ring	11	8 (72.7)	< 0.005	7 (63.3)	< 0.01
Undiff. carcinoma	3	3 (100)		3 (100)
Lauren classification
Intestinal type	108	36 (33.3)b	18.18	34 (31.5)b	17.79
Diffuse type	40	29 (72.5)	< 0.005	28 (70.0)	< 0.005
Mixed type	15	10 (66.7)		11 (73.3)

^aPapillary vs Tubular, Mucinous and Signet ring;

^bIntestinal type vs Diffuse type. NS: No Significance